CBT-1 and Paclitaxel in Treating Patients With Refractory, Recurrent, or Advanced Metastatic Solid Tumors - Related Studies

CBT-1 and Paclitaxel in Treating Patients With Refractory, Recurrent, or Advanced Metastatic Solid Tumors

This study is currently recruiting participants.

Study NCT00658424. Last updated on November 13, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Cancer

2	Interventions listed in this trial
		MDR modulator CBT-1
		paclitaxel
		technetium 99m sestamibi

3	More general drug interventions related to this trial
		Antimitotic Agents
		Antineoplastic Agents
		Antineoplastic Agents, Phytogenic
		Mitosis Modulators
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Therapeutic Uses
		Tubulin Modulators

4	Sponsors listed in this trial
		NCI - Center for Cancer Research-Medical Oncology
		National Cancer Institute (NCI)